Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 11/20 | 0.79 |
| ▸ | PDE6D | O43924 | 3/20 | 0.69 |
| ▸ | PDE6A | P16499 | 3/20 | 0.69 |
| ▸ | PDE6G | P18545 | 3/20 | 0.69 |
| ▸ | PDE6B | P35913 | 3/20 | 0.69 |
| ▸ | PDE6C | P51160 | 3/20 | 0.69 |
| ▸ | PDE6H | Q13956 | 3/20 | 0.69 |
| ▸ | PDE11A | Q9HCR9 | 3/20 | 0.69 |
| ▸ | ACHE | P22303 | 4/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | PDE4A | P27815 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.68 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.68 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7433593 | 0.93 | PDE5A (0.73) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7442714 | 0.92 | PDE5A (0.91) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7689509 | 0.89 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7449046 | 0.89 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7689505 | 0.89 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6783325 | 0.87 | PDE5A (0.88) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6783320 | 0.87 | PDE5A (0.88) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6783323 | 0.87 | PDE5A (0.88) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6506476 | 0.87 | PDE5A (0.88) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6508764 | 0.87 | PDE5A (0.84) | PDE5APDE6DPDE6APDE6GPDE6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6369059-B1 | INHIBITOR OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP SPECIFIC PDE); CARDIOVASCULAR DISORDERS; PYRAZINO(2',1':6,1)PYRIDO(3,4-B)INDOLE-1,4-DIONES | ICOS CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
| US-6143746-A | Combination of tadalafil and another drug for cGMP-specific PDE inhibition; erectile dysfunction, cardiovascular disorders | ICOS CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| US-6025494-A | CYCLIZATION OF DICARBONYL-SUBSTITUTED PYRIDOINDOLES YIELDS PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2000-02-15 | — | — | US | disclosed |
| EP-0740668-B1 | TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE | ICOS CORP (US) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | MKI67, PNPO, CDK4 | PDE5A 4371/4885PDE6D 4733/4885PDE6A 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.